Gilead Sciences (GILD) Misses Q4 EPS by 27c, Offers FY Guidance

Go back to Gilead Sciences (GILD) Misses Q4 EPS by 27c, Offers FY Guidance

Gilead Sciences (GILD) PT Lowered to $90 at Raymond James

February 5, 2019 9:00 AM EST

Raymond James analyst Steven Seedhouse lowered the price target on Gilead Sciences (NASDAQ: GILD) to $90.00 (from $92.00) while maintaining a Strong Buy rating.

... More

Gilead Sciences (GILD) PT Lowered to $100 at Citi

February 5, 2019 6:59 AM EST

Citi analyst Robyn Karnauskas lowered the price target on Gilead Sciences (NASDAQ: GILD) to $100.00 (from $106.00) while maintaining a Buy rating. 2019 guidance anticipates double-digit y/y HIV growth and HCV stabilization. The company guided for generic impact in HCV, Letairis and Ranexa of ~$2.2B with... More

Gilead Sciences (GILD) PT Raised to $89 at RBC Capital

February 5, 2019 6:46 AM EST

RBC Capital analyst Brian Abrahams raised the price target on Gilead Sciences (NASDAQ: GILD) to $89.00 (from $86.00) while maintaining a Outperform rating following fourth quarter results.

Abrahams commented, "Parsing out the one-time effects that inflated HIV but depressed earnings this quarter,... More

Gilead Sciences (GILD) Raises Quarterly Dividend 10.5% to $0.63; 3.6% Yield

February 4, 2019 4:03 PM EST

Gilead Sciences (NASDAQ: GILD) declared a quarterly dividend of $0.63 per share, or $2.52 annualized. This is a 10.5% increase from the prior dividend of $0.57.

The dividend will be payable on March 28, 2019, to stockholders of record on March 15, 2019, with an ex-dividend date of March 14,... More